Revenue Growth Acceleration
Revenue grew 15.0% YoY to $1.19B in Q1 FY2026, up from $1.04B in Q1 FY2025, indicating continued strong demand for DexCom's continuous glucose monitoring (CGM) products across its customer base.
DEXCOM INC is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: DexCom delivered a strong Q1 FY2026 with revenue rising 15.0% YoY to $1.19B, gross margin expanding 610 bps to 62.9%, and operating income nearly doubling to $255.3M, reflecting significant operational leverage.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue grew 15.0% YoY to $1.19B in Q1 FY2026, up from $1.04B in Q1 FY2025, indicating continued strong demand for DexCom's continuous glucose monitoring (CGM) products across its customer base.
Gross margin improved significantly to 62.9% from 56.9% in the prior year period, a 610 bps expansion, driven by a 1.2% decline in cost of revenue despite 15% revenue growth — suggesting meaningful manufacturing efficiencies and favorable product mix.
Operating income surged 90.9% YoY to $255.3M, with operating margin expanding 850 bps to 21.4% from 12.9%, as R&D expenses remained essentially flat (+0.1% YoY at $145.3M) while revenue scaled substantially.
Revenue
$1.19B
++15.05% YoY
EPS (Basic)
$0.52
++92.59% YoY
Gross Margin
62.9%
++6.10% YoY
Operating Income
$255.3M
++90.95% YoY
Add DXCM to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.